Vidal J - Search Results

1

Practical recommendations for the management of diabetes in patients with COVID-19.

Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RI, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JC, Ji L, Ludwig B. Bornstein SR, et al. Among authors: vidal j. Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-550. doi: 10.1016/S2213-8587(20)30152-2. Epub 2020 Apr 23. Lancet Diabetes Endocrinol. 2020. PMID: 32334646 Free PMC article. Review.

2

Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.

Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Rosenstock J, et al. Among authors: vidal j. Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13. Diabetes Obes Metab. 2018. PMID: 29974618 Free PMC article.

3

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.

Raccah D, Chou E, Colagiuri S, Gaàl Z, Lavalle F, Mkrtumyan A, Nikonova E, Tentolouris N, Vidal J, Davies M. Raccah D, et al. Among authors: vidal j. Diabetes Metab Res Rev. 2017 Mar;33(3):e2858. doi: 10.1002/dmrr.2858. Epub 2016 Oct 13. Diabetes Metab Res Rev. 2017. PMID: 27606888 Free PMC article.

4

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.

Morea N, Retnakaran R, Vidal J, Aroda VR, Liu M, Saremi A, Giorgino F. Morea N, et al. Among authors: vidal j. Diabetes Obes Metab. 2020 Sep;22(9):1683-1689. doi: 10.1111/dom.14077. Epub 2020 May 28. Diabetes Obes Metab. 2020. PMID: 32363634 Free PMC article. Clinical Trial.

5

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.

Vidal J, Malkin SJP, Hunt B, Martín V, Hallén N, Javier Ortega F. Vidal J, et al. Diabetes Ther. 2020 Feb;11(2):509-521. doi: 10.1007/s13300-019-00751-7. Epub 2020 Jan 10. Diabetes Ther. 2020. PMID: 31925724 Free PMC article.

6

Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.

Martín V, Vidal J, Malkin SJP, Hallén N, Hunt B. Martín V, et al. Among authors: vidal j. Adv Ther. 2020 Oct;37(10):4427-4445. doi: 10.1007/s12325-020-01464-1. Epub 2020 Aug 29. Adv Ther. 2020. PMID: 32862365

7

The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.

Franch-Nadal J, Malkin SJP, Hunt B, Martín V, Gallego Estébanez M, Vidal J. Franch-Nadal J, et al. Among authors: vidal j. Adv Ther. 2022 Jul;39(7):3180-3198. doi: 10.1007/s12325-022-02156-8. Epub 2022 May 12. Adv Ther. 2022. PMID: 35553372

8

Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.

Gómez-Huelgas R, Azriel S, Puig-Domingo M, Vidal J, de Pablos-Velasco P. Gómez-Huelgas R, et al. Among authors: vidal j. Int J Clin Pharmacol Ther. 2015 Mar;53(3):230-40. doi: 10.5414/CP202052. Int J Clin Pharmacol Ther. 2015. PMID: 25066229 Review.

9

Faecal microbiota composition and impulsivity in a cohort of older adults with metabolic syndrome.

Konstanti P, Gómez-Martínez C, Muralidharan J, Vioque J, Corella D, Fitó M, Vidal J, Tinahones FJ, Torres-Collado L, Coltell O, Castañer O, Moreno-Indias I, Atzeni A, Ruiz-Canela M, Salas-Salvadó J, Belzer C. Konstanti P, et al. Among authors: vidal j. Sci Rep. 2024 Nov 14;14(1):28075. doi: 10.1038/s41598-024-78527-8. Sci Rep. 2024. PMID: 39543142 Free PMC article.

10

Effects of parental socioeconomic status on offspring's fetal neurodevelopment.

Mathan J, Maximino-Pinheiro M, He Q, Rezende G, Menu I, Tissier C, Salvia E, Mevel K, Le Stanc L, Vidal J, Moyon M, Delalande L, Orliac F, Poirel N, Oppenheim C, Houdé O, Chaumette B, Borst G, Cachia A. Mathan J, et al. Among authors: vidal j. Cereb Cortex. 2024 Nov 5;34(11):bhae443. doi: 10.1093/cercor/bhae443. Cereb Cortex. 2024. PMID: 39526525

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,198 results

Search Page

Filters